GH Research (NASDAQ:GHRS) Shares Up 4.9% – Still a Buy?

Shares of GH Research PLC (NASDAQ:GHRS) traded up 4.9% during trading on Thursday . The company traded as high as $13.21 and last traded at $12.66. 39,796 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 163,339 shares. The stock had previously closed at $12.06.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on GHRS shares. Stifel Nicolaus increased their price target on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Cantor Fitzgerald began coverage on GH Research in a research report on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of GH Research in a research report on Monday, January 27th. Guggenheim initiated coverage on shares of GH Research in a report on Thursday, March 13th. They set a “buy” rating and a $32.00 price target on the stock. Finally, Royal Bank of Canada started coverage on GH Research in a research note on Friday, March 7th. They set an “outperform” rating and a $31.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $30.86.

GH Research Stock Performance

The business’s 50 day moving average is $11.64 and its 200 day moving average is $9.30. The company has a market capitalization of $658.21 million, a price-to-earnings ratio of -16.03 and a beta of 0.94.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06. Sell-side analysts predict that GH Research PLC will post -0.8 EPS for the current year.

Institutional Investors Weigh In On GH Research

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in shares of GH Research in the fourth quarter worth about $44,000. Two Sigma Investments LP acquired a new position in shares of GH Research during the 4th quarter worth approximately $117,000. Millennium Management LLC purchased a new position in shares of GH Research during the 4th quarter valued at approximately $145,000. AdvisorShares Investments LLC grew its stake in GH Research by 15.4% in the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock valued at $252,000 after acquiring an additional 4,806 shares during the period. Finally, Northern Trust Corp lifted its holdings in GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).